Funding trends, product pipelines, and the pace of R&D spending indicate demand is “poised to improve materially” for the rest of 2026, contend William Blair analysts.
The agreement follows FDA acceptance of next-generation sequencing for viral safety testing in Arovella's investigational new drug application for cancer treatment.
The addition increases the CDMO’s U.S. production capacity to 20,000 liters through its facility in California and its recent acquisition of a Rockville, Maryland site.
